A hierarchical assembly strategy to engineer dextran-enveloped polyurethane nanopolyplexes for robust ovarian cancer gene therapy
Source abstract
Abstract
A hierarchical assembly strategy is herein investigated to generate bio-responsive, dextran-enveloped, bioreducible polyurethane nanopolyplexes for nonviral gene therapy against ovarian tumor. Initially, a group of poly(urethane amine)s were designed and characterized for in vitro gene transfection. The polyurethane containing 1,4-bis(3-aminopropyl)piperazine residue (PUBAP) could induce the best in vitro transfection efficacy against SKOV-3 or A2780 ovarian cancer cells. Next, dextran-enveloped PUBAP polyplexes (e-polyplexes) were constructed by a hierarchical assembly procedure involving gene neutralization with PUBAP and subsequent gene condensation with a cationic dextran (SSDP800). Such dextran comprised dextran (15 kDa) as the main chain and multiple disulfide-linked branched polyethylenimine (BPEI) oligomers as the side grafts. Additionally, folate-dextran-enveloped PUBAP polyplexes (FA-e-polyplexes) were fabricated by folate-modified SSDP800. These nanoscale-enveloped polyplexes elicited an improved colloidal stability against salt ions and negatively charged heparin, efficient endosomal escaping, and bioreduction-triggered intracellular gene release. In vitro transfection against SKOV-3 cells illustrated that FA-e-polyplexes exerted higher transfection efficiency in the serum than e-polyplexes and 25 kDa BPEI-polyplexes. In vivo, FA-e-polyplexes yielded higher transgene expression level than e-polyplexes in an SKOV-3 tumor-bearing nude mouse model. In the tumor gene therapy with a small hairpin RNA silencing vascular endothelial growth factor, FA-e-polyplexes afforded higher tumor growth inhibition than polyplexes of folate-PEGylated PUBAP and 25 kDa linear polyethylenimine as positive controls. Importantly, such gene therapy had minor toxic effects on the health of the mouse. This work highlights a practical hierarchical assembly method to construct innovative enveloped polyurethane nanopolyplexes enabling robust ovarian cancer gene therapy. Statement of significance It is indispensable to rationally update binary cationic polyplexes into ternary polyplexes for vigorous tumor gene therapy. In this work, we have confirmed that a hierarchical assembly strategy, by using initial gene neutralization and subsequent gene condensation, is facile and effective to promote cationic polyurethane polyplexes into ternary folate-dextran-enveloped polyurethane polyplexes with a relatively high gene-loading capacity. The enveloped polyplex system enables more efficient gene transfection than the PEGylated polyplex counterpart in ovarian cancer in vitro and in vivo, thereby affording robust ovarian cancer gene therapy. The development of innovative enveloped polyplexes may be a new direction for a non-viral gene delivery system.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (48)
Show source-provided references
1. Can advanced-stage ovarian cancer be cured?10.1038/nrclinonc.2015.224 ↗
2. Cancer screening in the United States, 2017: a review of current American cancer society guidelines and current issues in cancer screening10.3322/caac.21392 ↗
3. Overall survival following neoadjuvant chemotherapy vs primary cytoreductive surgery in women with epithelial ovarian cancer analysis of the national cancer database10.1001/jamaoncol.2016.4411 ↗
4. Preclinical and clinical development of siRNA-based therapeutics10.1016/j.addr.2015.01.007 ↗
5. Whole-genome characterization of chemoresistant ovarian cancer10.1038/nature14410 ↗
6. Vectors and strategies for nonviral cancer gene therapy10.1517/14712598.2016.1134480 ↗
7. Polymeric oncolytic adenovirus for cancer gene therapy10.1016/j.jconrel.2015.10.009 ↗
8. Non-viral nucleic acid containing nanoparticles as cancer therapeutics10.1080/17425247.2016.1190707 ↗
9. Ovarian carcinoma cells are effectively transfected by polyethylenimine (PEI) derivatives10.1038/sj.cgt.7700170 ↗
10. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids10.1093/nar/gni085 ↗
11. Dextran-peptide hybrid for efficient gene delivery10.1021/la500905z ↗
12. Virion-mimicking nanocapsules from pH-controlled hierarchical self-assembly for gene delivery10.1002/anie.200703203 ↗
13. Synthesis and characterization of polyrotaxanes consisting of cationic alpha-cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers10.1021/bm700472t ↗
14. Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex
15. In vivo gene delivery by nonviral vectors: overcoming hurdles?10.1038/mt.2012.79 ↗
16. Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly10.1016/j.biomaterials.2012.05.060 ↗
17. Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice10.1158/0008-5472.CAN-09-0061 ↗
18. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles10.1078/0171-9335-00363 ↗
19. Nanocarriers for the targeted treatment of ovarian cancers10.1016/j.biomaterials.2012.10.055 ↗
20. Advances in stimulus-responsive polymeric materials for systemic delivery of nucleic acids
21. Pyridylhydrazone-based PEGylation for pH-reversible lipopolyplex shielding10.1016/j.biomaterials.2010.09.032 ↗
22. Polyplex micelles with phenylboronate/gluconamide cross-linking in the core exerting promoted gene transfection through spatiotemporal responsivity to intracellular pH and ATP concentration10.1021/jacs.7b08816 ↗
23. A pH-responsive detachable PEG shielding strategy for gene delivery system in cancer therapy10.1021/acs.biomac.7b00080 ↗
24. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors10.1021/ja800336v ↗
25. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid10.1038/sj.gt.3302843 ↗
26. Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release10.1016/j.jconrel.2011.10.016 ↗
27. Multifunctional cationic polyurethanes designed for non-viral cancer gene therapy10.1016/j.actbio.2015.11.048 ↗
28. Dextranated poly(urethane amine)s designed for systemic gene delivery in ovarian cancer therapy10.1039/C7TB01641G ↗
29. Thermosensitive in situ-forming dextran-pluronic hydrogels through Michael addition10.1016/j.msec.2010.07.004 ↗
30. Multifunctional disulfide-based cationic dextran conjugates for intravenous gene delivery targeting ovarian cancer cells10.1021/mp4006672 ↗
31. Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration10.1016/j.addr.2017.07.021 ↗
32. Challenges in DNA delivery and recent advances in multifunctional polymeric DNA delivery systems10.1021/acs.biomac.7b00803 ↗
33. Synthesis of novel biodegradable cationic polymer: N,N-diethylethylenediamine polyurethane as a gene carrier10.1021/bm049763v ↗
34. Self-assembly of biodegradable polyurethanes for controlled delivery applications10.1039/c2sm07402h ↗
35. Novel bioreducible poly(amido amine)s for highly efficient gene delivery10.1021/bc060200l ↗
36. Disulfide-functional poly(amido amine)s with tunable degradability for gene delivery10.1016/j.jconrel.2016.08.021 ↗
37. Bioreducible dextran-polyethylenimine conjugates regulate transgene expression distribution in vivo10.1039/C4TB01927J ↗
38. Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system10.1016/j.addr.2007.10.007 ↗
39. Multi-responsive “Turn-On” nanocarriers for efficient site-specific gene delivery in vitro and in vivo10.1002/adhm.201600710 ↗
40. Artificial virus delivers CRISPR-Cas9 system for genome editing of cells in mice10.1021/acsnano.6b04261 ↗
41. Overexpression of folate binding protein in ovarian cancers10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F ↗
42. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer
43. Esterase-activated charge-reversal polymer for fibroblast-exempt cancer gene therapy10.1002/adma.201603095 ↗
44. Redox-responsive amphipathic dextran nanomicelles for solid tumor therapy10.1166/jbn.2016.2314 ↗
45. Gene delivery nanoparticles to modulate angiogenesis10.1016/j.addr.2016.11.003 ↗
46. Tumor-targeted delivery of siRNA by self-assembled nanoparticles10.1038/sj.mt.6300323 ↗
47. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy10.1016/j.biomaterials.2017.09.021 ↗
48. EGFR and CD44 dual-targeted multifunctional hyaluronic acid nanogels boost protein delivery to ovarian and breast cancers in vitro and in vivo10.1021/acsami.7b06879 ↗